PHARMARON BIOLOGICS (UK) LTD
Get an alert when PHARMARON BIOLOGICS (UK) LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-06-03 (in 1mo)
Last made up 2025-05-20
Watchouts
Cash
£12M
+6.6% vs 2023
Net assets
—
Equity attributable
Employees
187
+2.2% vs 2023
Profit before tax
-£311K
+68.9% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
The directors believe that preparing the financial statements on the going concern basis is appropriate. Forecasts prepared on the basis of the current costs model show that the Company will need financial support from its ultimate parent, Pharmaron. The directors have received a letter of support from Pharmaron for a period of 12 months from the date of approval of these financial statements in order to ensure that the Company can meet its obligations as they fall due.
Profit before tax
3-year trend · vs Health Care median
Accounts
3-year trend · latest reflected 2024-12-31
| Metric | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Turnover | — | — | — | |
| Operating profit | — | — | — | |
| Profit before tax | — | -£1,001,087 | -£311,147 | |
| Net profit | — | — | — | |
| Cash | — | £11,097,343 | £11,831,577 | |
| Total assets less current liabilities | — | — | — | |
| Net assets | — | — | — | |
| Equity | £21,919,695 | £59,879,869 | £75,742,104 | |
| Average employees | — | 183 | 187 | |
| Wages | — | £11,481,476 | £11,235,855 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The directors believe that preparing the financial statements on the going concern basis is appropriate. Forecasts prepared on the basis of the current costs model show that the Company will need financial support from its ultimate parent, Pharmaron. The directors have received a letter of support from Pharmaron for a period of 12 months from the date of approval of these financial statements in order to ensure that the Company can meet its obligations as they fall due.”
Significant events
- “The Company continued to make significant investment in capital assets during 2024 to replace end of life systems and develop innovative technologies to remain competitive in the marketplace and comply with UK and global regulatory standards.”
- “The Company continued its ambitious £89.3m, 8,000m2 expansion project on site in Liverpool.”
- “The building shell was completed May 2025.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| LEWINTON, Stephen | Secretary | 2021-04-30 | — | — |
| LEWINTON, Stephen Christopher, Mr. | Director | 2021-10-26 | Apr 1966 | British |
| LOU, Boliang, Dr | Director | 2021-04-30 | Sep 1963 | American |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BATE, Anita Susan | Secretary | 2004-06-01 | 2010-01-28 |
| HARAN, Patricia Maria | Secretary | 2018-02-19 | 2021-04-30 |
| NELLIGAN, Tom | Secretary | 2015-11-03 | 2017-10-13 |
| ROTHWELL, Neil Julian | Secretary | 2002-11-12 | 2004-06-01 |
| TOMKINS, Judith | Secretary | 2018-02-19 | 2020-10-02 |
| HALLIWELLS SECRETARIES LIMITED | Corporate Nominee Secretary | 2002-09-24 | 2002-11-12 |
| BISARO, Paul Mino | Director | 2010-01-28 | 2015-11-03 |
| BROWN, Crawford David, Dr | Director | 2002-11-12 | 2021-04-30 |
| BUCHEN, David Adam | Director | 2010-01-28 | 2015-05-01 |
| STEWART, Janice Elizabeth | Director | 2014-08-13 | 2017-06-30 |
| WILKINSON, Fred, Dr | Director | 2010-01-28 | 2014-04-25 |
| HALLIWELLS DIRECTORS LIMITED | Corporate Nominee Director | 2002-09-24 | 2002-11-12 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Pharmaron Beijing Co Ltd | Corporate entity | Shares 75–100% | 2021-04-30 | Ceased 2021-08-02 |
| Pharmaron Biologics (Uk) Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-04-30 | Active |
| Abbvie Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-05-08 | Ceased 2021-04-30 |
| Agn Sundry Llc | Corporate entity | Shares 75–100% | 2019-04-01 | Ceased 2019-04-01 |
| Allergan Plc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-05-31 | Ceased 2020-05-08 |
| Eden Biopharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2018-05-31 |
Filing timeline
Last 20 of 110 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-22 | AA | accounts | Accounts with accounts type full | |
| 2025-06-02 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-01-23 | RESOLUTIONS | resolution | Resolution | |
| 2025-01-22 | SH01 | capital | Capital allotment shares | |
| 2025-01-16 | RESOLUTIONS | resolution | Resolution | |
| 2024-07-04 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-06-03 | AA | accounts | Accounts with accounts type full | |
| 2023-09-22 | AA | accounts | Accounts with accounts type full | |
| 2023-07-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-02-09 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2022-10-06 | AA | accounts | Accounts with accounts type full | |
| 2022-07-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-10-27 | AP01 | officers | Appoint person director company with name date | |
| 2021-09-07 | AA | accounts | Accounts with accounts type full | |
| 2021-08-31 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2021-08-24 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2021-08-02 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2021-05-14 | RESOLUTIONS | resolution | Resolution | |
| 2021-05-11 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2021-05-11 | PSC07 | persons-with-significant-control | Cessation of a person with significant control |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 1
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
+6.6%
£11,097,343 £11,831,577
-
Net assets
—
Not reported
-
Employees
+2.2%
183 187
-
Profit before tax
+68.9%
-£1,001,087 -£311,147
-
Wages
-2.1%
£11,481,476 £11,235,855
Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers